- Trials with a EudraCT protocol (286)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
286 result(s) found for: Renal ultrasound.
Displaying page 3 of 15.
EudraCT Number: 2018-002088-25 | Sponsor Protocol Number: N-003-CRD003 | Start Date*: 2019-01-11 | |||||||||||
Sponsor Name:Noorik Biopharmaceuticals AG | |||||||||||||
Full Title: A Phase II, Single-arm, Open-Label Study to Characterise the Effect on Portal Pressure, the Effect on Renal Function and the Pharmacokinetic Profile of N-003 in Patients with Decompensated Cirrhosis | |||||||||||||
Medical condition: decompensated liver cirrhosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001346-17 | Sponsor Protocol Number: ALN-GO1-005 | Start Date*: 2020-02-20 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 (PH1) | |||||||||||||
Medical condition: Primary Hyperoxaluria Type 1 (PH1) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Completed) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) NL (Ongoing) Outside EU/EEA IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004301-41 | Sponsor Protocol Number: P170404J | Start Date*: 2018-10-15 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
[...]
1. ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
2. Assistance Publique-Hopitaux de Paris(AP-HP) |
|||||||||||||
Full Title: FURosemide Stress Test to predict need of Renal Replacement THERapy in Ischemic Acute Tubular Necrosis in Intensive Care Units | |||||||||||||
Medical condition: FURosemide Stress Test to predict need of Renal Replacement THERapy in Ischemic Acute Tubular Necrosis in Intensive Care Units | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-006557-25 | Sponsor Protocol Number: RAPYD-STUDY | Start Date*: 2007-12-20 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE | |||||||||||||
Full Title: RAPAMYCIN FOR TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE | |||||||||||||
Medical condition: ADPKD type I | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000306-70 | Sponsor Protocol Number: 2009/07 | Start Date*: 2008-01-29 | |||||||||||
Sponsor Name:University of Dundee | |||||||||||||
Full Title: The effect of metformin on biomarker activity in primary breast cancer | |||||||||||||
Medical condition: Women with histologically proven operable primary, invasive breast cancer of ≥ 1cm in size. The study will involve women from the east of Scotland. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016653-17 | Sponsor Protocol Number: FARM73452X | Start Date*: 2010-04-13 | ||||||||||||||||||||||||||
Sponsor Name:AZIENDA UNITA` SANITARIA LOCALE N 12 DI VIAREGGIO | ||||||||||||||||||||||||||||
Full Title: TREATMENT OF HYPOTENSION IN EXTREMELY PRETERM INFANTS: A MULTICENTER RANDOMIZED CONTROLLED TRIAL | ||||||||||||||||||||||||||||
Medical condition: HYPOTENSION IN EXTREMELY PRETERM INFANTS | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002852-17 | Sponsor Protocol Number: SSH-IC | Start Date*: 2020-06-02 | |||||||||||
Sponsor Name:Marta Cobo Marcos | |||||||||||||
Full Title: Efficacy and Safety of Intravenous Furosemide administered with Hypertonic Saline Solution at the Heart Failure Day Hospital. SSH-IC study | |||||||||||||
Medical condition: Decompensated Heart Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000967-10 | Sponsor Protocol Number: RC31/14/7441 | Start Date*: 2019-05-24 |
Sponsor Name:University Hospital Toulouse | ||
Full Title: Autologous transplantation of Adipose tissue derived mesenchymal Stroma/stem Cells (ASC) in patients with critical limb ischemia: a phase II study (ACellDream 2). | ||
Medical condition: Patients with rest pain or ischemic ulcers/gangrene of the lower limb and without option for revascularization or poor option. Or patients with with rest pain or ischemic ulcers and persistent CL... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002773-21 | Sponsor Protocol Number: 89Zr-TLX250-003 | Start Date*: 2019-04-10 |
Sponsor Name:TELIX International Pty Ltd | ||
Full Title: A confirmatory, prospective, open-label, multi-centre phase 3 study to evaluate diagnostic performance of 89Zirconium-labelled girentuximab(89Zr-TLX250) to non-invasively detect clear cell renal ce... | ||
Medical condition: Patients with an indeterminate renal mass (IRM) detected on contrast-enhanced abdominal MR imaging or equivalent standard of care imaging, clinically suspicious for renal cell carcinoma and schedul... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) BE (Completed) ES (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2018-003141-42 | Sponsor Protocol Number: EX9924-4473 | Start Date*: 2019-07-03 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) NL (Completed) GB (GB - no longer in EU/EEA) SK (Completed) DE (Completed) BE (Completed) AT (Completed) ES (Ongoing) CZ (Completed) FR (Completed) HR (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005552-41 | Sponsor Protocol Number: ALADIN | Start Date*: 2006-02-20 | |||||||||||
Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI | |||||||||||||
Full Title: Effect of long-acting somatostatin on disease progression in nephropathy due to autosomal dominant polycystic disease a long-term three year follow-up study | |||||||||||||
Medical condition: Autosomal Dominant Polycystic Kidney Disease ADPKD | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000255-13 | Sponsor Protocol Number: 11-019 | Start Date*: 2012-06-20 | |||||||||||
Sponsor Name:Portola Pharmaceuticals, Inc. | |||||||||||||
Full Title: Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Me... | |||||||||||||
Medical condition: Prophylaxis of venous thromboembolism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) LV (Completed) DE (Completed) ES (Completed) GB (Completed) PL (Completed) LT (Completed) AT (Completed) DK (Completed) CZ (Completed) BG (Completed) IT (Completed) FI (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002547-29 | Sponsor Protocol Number: ATB-203 | Start Date*: 2019-11-21 | ||||||||||||||||||||||||||
Sponsor Name:Atox Bio | ||||||||||||||||||||||||||||
Full Title: Phase 2 randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of Reltecimod as compared to placebo in addition to standard of care in patients with ... | ||||||||||||||||||||||||||||
Medical condition: Acute kidney injury due to intra-abdominal infection/sepsis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Completed) BE (Prematurely Ended) NL (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004419-38 | Sponsor Protocol Number: CL3-95008-001 | Start Date*: 2018-10-04 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7 to less than 18 years old with Autism Spectrum Disorder. A 6-month randomised, double-blind, place... | |||||||||||||
Medical condition: Autism Spectrum Disorder (ASD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) DE (Completed) ES (Prematurely Ended) NL (Completed) HU (Completed) PT (Completed) PL (Prematurely Ended) IT (Completed) IE (Prematurely Ended) CZ (Ongoing) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000157-41 | Sponsor Protocol Number: UoL001343 | Start Date*: 2019-06-07 | |||||||||||
Sponsor Name:The University of Liverpool | |||||||||||||
Full Title: NEO21-RS: A phase II randomised study of the cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with oestrogen suppression therapy versus oestrogen suppression therapy alone as neoadj... | |||||||||||||
Medical condition: ER-positive, HER2-negative breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001546-17 | Sponsor Protocol Number: GBG40 | Start Date*: Information not available in EudraCT |
Sponsor Name:German Breast Group | ||
Full Title: GeparQuattro: A randomized phase III study exploring the efficacy of Capecitabine given concomitantly or in sequence to EC - Doc with or without Trastuzumab as neoadjuvant treatment of primary brea... | ||
Medical condition: Primary breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002734-37 | Sponsor Protocol Number: Uni-Koeln-4067 | Start Date*: 2021-03-01 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: Open-Label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy with Liposomal Irinotecan Combined with Oxaliplatin and 5-Fluorouracil/Folin... | |||||||||||||
Medical condition: Hepatic Oligometastatic Adenocarcinoma of the Pancreas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004368-23 | Sponsor Protocol Number: 20121005 | Start Date*: 2012-11-02 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: Feasible strategy for preventing blood clots in critically ill patients with acute kidney Injury | |||||||||||||
Medical condition: venous thromboembolism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000535-18 | Sponsor Protocol Number: ML17632 | Start Date*: 2005-05-18 |
Sponsor Name:Roche Pharma (Schweiz) AG | ||
Full Title: Prospective, multicenter study to evaluate the renal safety of 6 mg ibandronic acid infusions over 15 min or 60 min in patients with metastatic bone disease due to breast cancer. | ||
Medical condition: The target population for this trial are female patients with primary breast cancer with metastatic bone disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-017245-64 | Sponsor Protocol Number: OG09/9146 | Start Date*: 2010-09-07 |
Sponsor Name:Leeds Teaching Hospitals NHS Trust | ||
Full Title: The effect of metformin co-treatment in hormone-replacement frozen embryo replacement cycles in women with polycystic ovary syndrome. | ||
Medical condition: Polycystic Ovary Syndrome | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
